Cervical cancer

Immunotherapy
#Cancer immunotherapy #Cervical cancer #National Institute for Health and Care Excellence (NICE) #Regeneron Pharmaceuticals

NICE recommends immunotherapy to treat cervical cancer 

The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab for the treatment of advanced cervical cancer.  The immunotherapy, developed by biotechnology company Regeneron, has been recommended in England and Wales to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults.   This… Read More

#News #Regulatory

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

DDW Highlights: 9 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer drug demonstrated it could reduce tumours by as much as… Read More

#Podcasts

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

This week in Drug Discovery (1 June – 5 June) 

News round-up for 1 June – 5 June by Bruno Quinney, Content Team at DDW.  This week, a cancer drug has demonstrated it could reduce tumours by as much as 55%. Elsewhere, AI has been a recurrent theme in both clinical trials and drug development.   The top stories:… Read More

#News

Tumour microenvironment
#Cancer research #Cervical cancer #Colorectal cancer #Head and neck cancer

Drug could reduce tumours by 55%, results show 

An experimental drug could shrink tumours by up to 55%, results show.  GRWD5769, developed by biotech company Greywolf Therapeutics, is a first-in-class oral small molecule inhibitor of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1), an enzyme that regulates tumour antigen presentation on MHC-I.  The drug works by… Read More

#Cancer Research #News

Nasal spray
#Cancer treatment #Cervical cancer #HPV #Immunology / Virology & Vaccines #Oncology

Scientists create nasal vaccine for treating cervical cancer

Researchers at Chiba University in Japan have developed a new nasal therapeutic vaccine as a non-invasive treatment option for cervical cancer.   Cervical cancer is primarily caused by the human papillomavirus (HPV), but there are no approved therapeutic medicines to treat existing infections or HPV-associated cancers. … Read More

#Cancer Research #Editor's Choice #News